Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Esperion Therapeutics (ESPR) PT Raised to $130 at Needham & Company
May 8, 2015 7:46 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and boosted his price target on Esperion Therapeutics (NASDAQ: ESPR) to $130.00 (from $104.00), citing multiple value-creating events through year-end.
Esperion has submitted briefing documents to the FDA and expects to be able to hold... More
